Drug intelligence / Profile preview

Soloxine

Development stage: Unknown
Lead developer: Virbac
Modality: Small Molecules
Administration: Oral

Overview

Soloxine is a veterinary synthetic thyroid hormone replacement therapy containing levothyroxine sodium (T4). Manufactured by Virbac, it is indicated for the treatment of hypothyroidism in dogs. As a synthetic form of the naturally occurring thyroid hormone thyroxine, it acts as a substrate for physiologic deiodination to liothyronine (T3), the active form of the hormone. This process restores normal metabolic function and resolves clinical signs associated with thyroid deficiency, such as lethargy, weight gain, and skin issues. It is considered a standard-of-care treatment in canine medicine and is administered orally in tablet form.

Brand names: Soloxine
Other names: levothyroxine sodium

Targets

THRB (Thyroid hormone receptor beta)THRA (Thyroid hormone receptor alpha)

Beyond the preview

Go deeper on Soloxine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soloxine.

Explore the full profile